Clinical Rheumatology

, Volume 28, Issue 9, pp 1079–1082 | Cite as

Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study

  • Tatiana Reitblat
  • Doron Zamir
  • Ilia Polishchuck
  • Galina Novochatko
  • Stephen Malnick
  • Leonid Kalichman
Brief Report

Abstract

The symptoms of irritable bowel syndrome (IBS) are commonly seen in fibromyalgia (FM) patients. This study aimed to evaluate the effect of 5-hydroxytryptamin-4 receptor partial agonist (tegaserod) on the symptoms of FM among the patients who receive the medicine because of IBS. Forty-one female patients with IBS and constipation, which were subjects to tegaserod treatment, were examined by rheumatologist and 14 were found to suffer from FM. The fibromyalgia impact questionnaire (FIQ) and clinical examination were done before tegaserod treatment and 1 month after. The IBS status, the total FIQ score, the number of tender points and pain in tender points were lowered significantly after the treatment (p < 0.001 for all variables). The results of this pilot study provide the preliminary evidence that FM patients can benefit from treatment by 5-hydroxytryptamin-4 receptor partial agonist. Additional studies are needed to support this conclusion.

Keywords

Comorbidity Fibromyalgia Irritable bowel syndrome Tegaserod 

References

  1. 1.
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P et al (1990) The American College of Rheumatology 1990 criteria for the classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  2. 2.
    Yunus MB, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL (1981) Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11:151–171PubMedCrossRefGoogle Scholar
  3. 3.
    Goldenberg DL (1987) Fibromyalgia syndrome: an emerging but controversial condition. JAMA 257:2782–2787PubMedCrossRefGoogle Scholar
  4. 4.
    Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L (1992) Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92:363–367PubMedCrossRefGoogle Scholar
  5. 5.
    Clouw DJ, Chrousos GP (1997) Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenetic mechanism. Neuroimmunomodulation 4:134–153Google Scholar
  6. 6.
    Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D (1999) Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterology 94:3541–3546CrossRefGoogle Scholar
  7. 7.
    Veale D, Kavanagh G, Fielding JF, Fitzgerald O (1991) Primary fibromyalgia and the irritable bowel syndrome. Br J Rheumatol 30:220–222PubMedCrossRefGoogle Scholar
  8. 8.
    Aaron LA, Buchwald D (2001) Fibromyalgia and other unexplained clinical conditions. Cur Rheum Rep 3:116–122CrossRefGoogle Scholar
  9. 9.
    Everhart JE, Renault PF (1991) Irritable bowel syndrome in office based practice in the United States. Gastroenterology 100:998–1005PubMedGoogle Scholar
  10. 10.
    Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101:927–934PubMedGoogle Scholar
  11. 11.
    Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97:S7–S26PubMedGoogle Scholar
  12. 12.
    Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA (2001) Irritable bowel syndrome in twins: hereditary and social learning both contribute to etiology. Gastroenterology 121:799–804PubMedCrossRefGoogle Scholar
  13. 13.
    Moldofsky H, Warsh JJ (1978) Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 5:65–71PubMedCrossRefGoogle Scholar
  14. 14.
    Moldofsky H (1982) Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 33:51–57PubMedGoogle Scholar
  15. 15.
    Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K (1989) Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol Suppl 19:158–163PubMedGoogle Scholar
  16. 16.
    Prior A, Read NW (1993) Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 7:175–180PubMedCrossRefGoogle Scholar
  17. 17.
    Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P, TegaSwiss Study Group (2005) Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel disease syndrome. Eur J Gastroenerol Hepatol 17:421–427CrossRefGoogle Scholar
  18. 18.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 4:CD003960PubMedGoogle Scholar
  19. 19.
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl 2):II43–II47PubMedGoogle Scholar
  20. 20.
    Buskila D, Neumann L (1996) Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the fibromyalgia impact questionnaire. J Rheumatol 23:903–906PubMedGoogle Scholar
  21. 21.
    Hrycaj P, Stratz T, Mennet P, Müller W (1996) Pathogenetic aspects of responsiveness to ondansetron (5HT type 3 receptor antagonist) in patients with primary fibromyalgia syndrome—a preliminary study. J Rheumatol 23:1418–1423PubMedGoogle Scholar
  22. 22.
    Spath M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger CC, Haus U, Färber L, Pongratz D, Müller W (2004) Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scan J Rheumatol 33:267–270CrossRefGoogle Scholar
  23. 23.
    Weinstock LB, Fern SE, Duntley SP (2008) Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 53:1252–1256PubMedCrossRefGoogle Scholar
  24. 24.
    Yunus MB, Aldag JC (1996) Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 312:1339PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Tatiana Reitblat
    • 1
  • Doron Zamir
    • 2
    • 3
  • Ilia Polishchuck
    • 2
  • Galina Novochatko
    • 2
  • Stephen Malnick
    • 4
  • Leonid Kalichman
    • 5
  1. 1.Rheumatology UnitBarzilai Medical CenterAshkelonIsrael
  2. 2.Internal Medicine Department “D”Barzilai Medical CenterAshkelonIsrael
  3. 3.Gastroenterology UnitBarzilai Medical CenterAshkelonIsrael
  4. 4.Institute of Gastrointestinal and Liver Diseases and Medicine Department CKaplan HospitalRehovotIsrael
  5. 5.Department of Physical Therapy, Recanati School for Community Health Professions, Faculty of Health SciencesBen-Gurion University of the NegevBeer ShevaIsrael

Personalised recommendations